UroGen Pharma
URGN
71 hedge funds and large institutions have $469M invested in UroGen Pharma in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 7 closing their positions.
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
18% more funds holding
Funds holding: 60 → 71 (+11)
0.53% more ownership
Funds ownership: 62.07% → 62.61% (+0.53%)
3% less capital invested
Capital invested by funds: $482M → $469M (-$13.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $359K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.77M |
| 2 |
WCM
Wildcat Capital Management
New York
|
+$5.76M |
| 3 |
DG
Delek Group
Herzliya,
Israel
|
+$4.63M |
| 4 |
Man Group
London,
United Kingdom
|
+$3.97M |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7M |
| 2 |
DP
DSAM Partners
London,
United Kingdom
|
-$6.35M |
| 3 |
Renaissance Technologies
New York
|
-$4.58M |
| 4 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$2.9M |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$957K |
URGN Hedge Fund Activity: Q3 2018 in Review
71 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2018, worth a combined $469M — down 2.8% from $482M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new URGN positions and 7 closed out — a net gain of 11 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was Credit Suisse, adding an estimated $6.77M. The largest seller was Fidelity Investments, cutting an estimated $7M.
- 71 institutional investors held UroGen Pharma (URGN) as of Q3 2018, up from 60 in Q2 2018.
- Funds reported $469M of UroGen Pharma stock for Q3 2018, down 2.8% quarter-over-quarter.
- 18 funds opened new UroGen Pharma positions in Q3 2018 and 7 closed out, a net change of +11 holders.
- The largest UroGen Pharma buyer in Q3 2018 was Credit Suisse, an estimated $6.77M added.
- The largest UroGen Pharma seller in Q3 2018 was Fidelity Investments, an estimated $7M sold.
Based on aggregated 13F filings for Q3 2018.